• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Expanded clinical notes and medical images available to advance research

Expanded clinical notes and medical images available to advance research

by Truveta staff | May 1, 2024 | Data, News, Technology

Today we are excited to announce the availability of expanded concepts from clinical notes — including family history, medication details reported to providers, and complex concepts for a wide range of therapeutic areas from cardiology to rare disease and more –...
Outcomes and disparities for patients with aortic stenosis, classified by echocardiogram data

Outcomes and disparities for patients with aortic stenosis, classified by echocardiogram data

by Truveta Research | Mar 6, 2024 | Research, Research Insights

Disparities in time to treatment and treatment outcomes exist for people with severe aortic stenosis receiving TAVR and SAVR procedures. We studied the rate of people who receive TAVR, SAVR, aortic valve repair, and aortic balloon valvuloplasty procedures and time to...
Truveta named SXSW Innovation Awards finalist in Artificial Intelligence for AI-enabled health research

Truveta named SXSW Innovation Awards finalist in Artificial Intelligence for AI-enabled health research

by Truveta staff | Jan 25, 2024 | News

Today Truveta is excited to announce that the company is a finalist at the 2024 South by Southwest (SXSW) Innovation Awards recognizing Truveta Language Model (TLM) in the Artificial Intelligence (AI) category. This prestigious accolade not only acknowledges...

Share this


Recent posts

  • Real-world survival outcomes for CRT and CCM therapies align with landmark trials
  • Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
  • Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice